SAB Biotherapeutics, Inc. financial data

Symbol
SABS, SABSW on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
2100 East 54 Th Street North, Sioux Falls, South Dakota
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Big Cypress Acquisition Corp. (to 10/22/2021)
Latest financial report
Q1 2024 - May 20, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 300 % +113%
Debt-to-equity 51 % -23.6%
Return On Equity -110 % -25%
Return On Assets -72.8 % -38.1%
Operating Margin -1.62 K % -592%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 9.23 M shares -82.4%
Common Stock, Shares, Outstanding 9.23 M shares -81.7%
Entity Public Float 30.7 M USD -6.22%
Common Stock, Value, Issued 929 USD -81.8%
Weighted Average Number of Shares Outstanding, Basic 9.24 M shares +83.4%
Weighted Average Number of Shares Outstanding, Diluted 9.24 M shares +83.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 85.5 K USD -98.7%
Revenue from Contract with Customer, Excluding Assessed Tax 2.6 M USD -79.5%
Research and Development Expense 20.1 M USD -27.2%
General and Administrative Expense 24.5 M USD +67.6%
Operating Income (Loss) -42.1 M USD -42%
Nonoperating Income (Expense) 2.2 M USD -10.8%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -39.9 M USD -46.9%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -39.9 M USD -47.2%
Earnings Per Share, Basic -6.72 USD/shares -16.1%
Earnings Per Share, Diluted -0.54 USD/shares +63%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14 M USD +7.46%
Cash, Cash Equivalents, and Short-term Investments 15 M USD -62%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD -100%
Assets, Current 47 M USD +212%
Property, Plant and Equipment, Net 17.9 M USD -20%
Operating Lease, Right-of-Use Asset 1.08 M USD +12.5%
Assets 71.4 M USD +67.3%
Accounts Payable, Current 1.24 M USD -14.2%
Employee-related Liabilities, Current 1.92 M USD
Liabilities, Current 8.3 M USD -39.2%
Operating Lease, Liability, Noncurrent 555 K USD +144%
Liabilities 18.5 M USD +1.53%
Accumulated Other Comprehensive Income (Loss), Net of Tax -63.4 K USD
Retained Earnings (Accumulated Deficit) -95.1 M USD -72.2%
Stockholders' Equity Attributable to Parent 52.8 M USD +116%
Liabilities and Equity 71.4 M USD +67.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.8 M USD -569%
Net Cash Provided by (Used in) Financing Activities -394 K USD -9.63%
Net Cash Provided by (Used in) Investing Activities -31.4 M USD -147126%
Common Stock, Shares Authorized 800 M shares +63.3%
Common Stock, Shares, Issued 9.28 M shares -81.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -42.5 M USD -2041%
Interest Paid, Excluding Capitalized Interest, Operating Activities 66.2 K USD -15.5%
Deferred Tax Assets, Valuation Allowance 19.2 M USD +55.9%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 22.1 M USD +39.5%
Operating Lease, Liability 1.1 M USD +47.2%
Payments to Acquire Property, Plant, and Equipment 129 K USD +506%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -5.12 M USD +30.4%
Lessee, Operating Lease, Liability, to be Paid 1.19 M USD +52.9%
Property, Plant and Equipment, Gross 29.8 M USD +0.77%
Operating Lease, Liability, Current 543 K USD +4.79%
Lessee, Operating Lease, Liability, to be Paid, Year Two 310 K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 372 K USD +0.99%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure +32.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 93.7 K USD +182%
Lessee, Operating Lease, Liability, to be Paid, Year Three 310 K USD
Deferred Tax Assets, Operating Loss Carryforwards 10.3 M USD +84.2%
Preferred Stock, Shares Issued 42.2 K shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 0 USD
Operating Lease, Payments 713 K USD -29.2%
Additional Paid in Capital 153 M USD +80.3%
Preferred Stock, Shares Outstanding 42.2 K shares
Depreciation, Depletion and Amortization 4.72 M USD +37.5%
Deferred Tax Assets, Net of Valuation Allowance 2.86 M USD -18.2%
Share-based Payment Arrangement, Expense 2.44 M USD +2.48%
Interest Expense 299 K USD -7.04%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%